This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Hycanthone
Accession Number
DB14061
Type
Small Molecule
Groups
Experimental
Description

Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.

Structure
Thumb
Synonyms
  • 1-((2-(Diethylamino)ethyl)amino)-4-(hydroxymethyl)-9H-thioxanthen-9-one
  • 1-((2-(Diethylamino)ethyl)amino)-4-(hydroxymethyl)thioxanthen-9-one
  • Hicantona
  • Hycanthon
  • Hycanthonum
  • Lucanthone metabolite
External IDs
Win 24,933 / WIN 24933
Product Ingredients
IngredientUNIICASInChI Key
Hycanthone mesylate48830NW22A23255-93-8LOEQGPPJCCUXEJ-UHFFFAOYSA-N
Categories
UNII
2BXX5EVN2A
CAS number
3105-97-3
Weight
Average: 356.48
Monoisotopic: 356.155849195
Chemical Formula
C20H24N2O2S
InChI Key
MFZWMTSUNYWVBU-UHFFFAOYSA-N
InChI
InChI=1S/C20H24N2O2S/c1-3-22(4-2)12-11-21-16-10-9-14(13-23)20-18(16)19(24)15-7-5-6-8-17(15)25-20/h5-10,21,23H,3-4,11-13H2,1-2H3
IUPAC Name
1-{[2-(diethylamino)ethyl]amino}-4-(hydroxymethyl)-9H-thioxanthen-9-one
SMILES
CCN(CC)CCNC1=C2C(=O)C3=CC=CC=C3SC2=C(CO)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AMultidrug resistance protein 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Hycanthone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Hycanthone.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Hycanthone.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Hycanthone.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Hycanthone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Hycanthone.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Hycanthone.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Hycanthone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Hycanthone.
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Hycanthone.
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D00541
ChemSpider
3508
BindingDB
50066721
ChEBI
52768
ChEMBL
CHEMBL22077
Wikipedia
Hycanthone

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0168 mg/mLALOGPS
logP3.87ALOGPS
logP3.74ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)14.79ChemAxon
pKa (Strongest Basic)8.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area52.57 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity107.79 m3·mol-1ChemAxon
Polarizability40.57 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Palmeira A, Rodrigues F, Sousa E, Pinto M, Vasconcelos MH, Fernandes MX: New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors. Chem Biol Drug Des. 2011 Jul;78(1):57-72. doi: 10.1111/j.1747-0285.2011.01089.x. Epub 2011 Mar 29. [PubMed:21235729]
  2. Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G: Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Updat. 2017 May;32:23-46. doi: 10.1016/j.drup.2017.10.003. Epub 2017 Oct 16. [PubMed:29145976]
  3. Miguel P. Rocha, Florentino Fernández Riverola, Hagit Shatkay, Juan Manuel Corchado Rodríguez (2010). Advances in Bioinformatics. Springer.

Drug created on June 14, 2018 13:40 / Updated on November 02, 2018 09:15